Evidence map›Paper›PMID 40872797›Full record

ArticleViruses2025

SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression.

Ivo Schirmeister, Nicolas Eckert, Sebastian Weigang, Jonas Fuchs, Lisa Kern, Georg Kochs, Anne Halenius

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ivo SchirmeisterInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.
Nicolas EckertInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.ORCID 0009-0006-2116-5973
Sebastian WeigangInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0002-8415-6920
Jonas FuchsInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.
Lisa KernInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-9365-4975
Georg KochsInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.
Anne HaleniusInstitute of Virology, Medical Center University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-6335-1017

Funding

Deutsche Forschungsgemeinschaft HA 6035/2-2
6 · The paper itself

Abstract

Human leukocyte antigen class I (HLA-I) molecules present intracellular peptides on the cell surface to enable CD8+ T cells to effectively control viral infections. Many viruses disrupt this antigen presentation pathway to evade immune detection. In this study, we demonstrate that SARS-CoV-2 Nsp1 impairs both the constitutive and interferon-γ (IFN-γ)-induced upregulation of HLA-I. Moreover, Nsp1 also blocks IFN-γ-induced expression of HLA-II. We found that, contrary to previously published work, the early SARS-CoV-2 B 1.1.7 Alpha variant lacking the accessory protein ORF8 retained full capacity to downregulate HLA-I, comparable to an ORF8-expressing wild-type isolate. While ectopic overexpression of ORF8 could reduce HLA-I surface levels, this effect was only observed at high expression levels. In contrast, moderate expression of the viral protein Nsp1 was sufficient to potently suppress both basal and IFN-γ-induced HLA-I, as well as HLA-II expression. To probe the underlying mechanism, we analyzed HLA-I-associated genes in previously published RNA-sequencing datasets and confirmed that Nsp1 reduces expression of components required for HLA-I biosynthesis and antigen processing. These findings identify Nsp1 as a key factor that impairs antigen presentation pathways, potentially contributing to the ability of SARS-CoV-2 to modulate immune recognition.

Indexed as

COVID-19Histocompatibility Antigens Class IHistocompatibility Antigens Class IISARS-CoV-2Viral Nonstructural ProteinsAntigen PresentationHEK293 CellsHumansInterferon-gammaViral ProteinsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInterferon-gammaORF1ab polyprotein, SARS-CoV-2ORF8 protein, SARS-CoV-2Viral Nonstructural ProteinsViral ProteinsMHCNsp1ORF8

Identifiers

PMID40872797
PMCPMC12390542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.